Drug Profile
Humantakinogene hadenovec - Flexion Therapeutics
Alternative Names: enekinragene inzadenovec; FX 201 - Flexion Therapeutics; GQ 203; PCRX-201Latest Information Update: 15 Mar 2024
Price :
$50
*
At a glance
- Originator Baylor College of Medicine
- Developer Flexion Therapeutics
- Class Analgesics; Anti-inflammatories; Antirheumatics; Gene therapies
- Mechanism of Action Gene transference; Interleukin-1 receptor antagonist expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Osteoarthritis; Pain
Most Recent Events
- 13 Mar 2024 Efficacy and adverse events data from a phase I trial in Osteoarthritis released by Pacira BioSciences
- 29 Feb 2024 Humantakinogene hadenovec - Flexion Therapeutics receives Regenerative Medicine Advanced Therapy (RMAT) status for Osteoarthritis in USA
- 31 Dec 2023 Flexion therapeutics has patents pending for PCRX 201 for treatment of degenerative disc disease (DDD), in USA